Pfizer Inc. ($PFE) Stock Forecast: Down 2.5% Today

What is Pfizer Inc.?

Pfizer (PFE) is a pharmaceutical company renowned for its diverse product portfolio, ranging from vaccines to medications for various health conditions. The market sentiment towards Pfizer has been optimistic, attributed to its solid track record of performance.

Why is Pfizer Inc. going down?

PFE stock is down 2.5% on Feb 4, 2025 15:35

• Pfizer surpassed earnings and revenue projections in Q4, demonstrating robust performance in its Seagen and COVID-19 product lines. However, despite this, the stock witnessed a downward trend.
• Concerns regarding Pfizer's sustainability of growth momentum, particularly in meeting financial expectations, could have prompted the market's negative response.
• Investors may have anticipated even stronger results from Pfizer, resulting in profit-taking and a temporary decline in stock value.
• The market movement may also be influenced by broader industry trends or sector-specific factors impacting pharmaceutical companies.

PFE Price Chart

PFE Technical Analysis

PFE News

Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook - Pfizer ( NYSE:PFE )

Pfizer's Q4 adjusted EPS was $0.63, surpassing the $0.47 consensus, while revenue rose 22% YoY to $17.76B, beating estimates of $17.40B. Paxlovid sales hit $727M, up $3.9B YoY due to a revenue reversal, while Vyndaqel sales rose 60% to $1.55B, and Eliquis grew 14% to $1.83B. On Tuesday, Pfizer ...

https://www.benzinga.com/general/biotech/25/02/43463168/pfizer-q4-earnings-revenue-and-eps-beat-seagen-and-covid-19-products-show-strength-issues-strong-

Pfizer ( PFE ) Beats Q4 Earnings and Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 31.25% and 1.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2408955/pfizer-pfe-beats-q4-earnings-and-revenue-estimates

Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.

https://www.cnbc.com/2025/02/04/pfizer-pfe-earnings-q4-2024.html

Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Pfizer ( NYSE:PFE )

Pfizer Inc. PFE will release its fourth-quarter financial results, before the opening bell, on Tuesday, Feb. 4, 2025. Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in the year-ago period.

https://www.benzinga.com/25/02/43455760/pfizer-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts

PepsiCo, Pfizer And 3 Stocks To Watch Heading Into Tuesday - NXP Semiconductors ( NASDAQ:NXPI ) , Electronic Arts ( NASDAQ:EA )

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects PepsiCo Inc. PEP to report quarterly earnings at $1.94 per share on revenue of $27.89 billion before the opening bell, according to data from ...

https://www.benzinga.com/news/earnings/25/02/43455233/pepsico-pfizer-and-3-stocks-to-watch-heading-into-tuesday

Trending Today

Bonk ($BONK) Crypto Forecast: Down 6.7% Today

Optimism ($OP) Crypto Forecast: Down 7.5% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.0% Today

Chainlink ($LINK) Crypto Forecast: Down 6.2% Today

Cardano ($ADA) Crypto Forecast: Down 5.5% Today

Solana ($SOL) Crypto Forecast: Down 5.7% Today

Mantle ($MNT) Crypto Forecast: Down 6.0% Today

Arbitrum ($ARB) Crypto Forecast: Down 7.3% Today

Ondo ($ONDO) Crypto Forecast: Down 5.4% Today

Pfizer Inc. Price History

15.10.2024 - PFE Stock was down 7.4%

• Pfizer's stock faced significant downward pressure due to concerns surrounding the appointment of a vaccine skeptic to lead the HHS by President-elect Donald Trump.
• This development led to a bearish response in Pfizer's stock price and also impacted other vaccine makers like Moderna, Novavax, and BioNTech.
• Despite the recent decline, there may be an opportunity for investors to consider purchasing Pfizer's stock as it is currently oversold, with analysts increasing earnings estimates, suggesting a potential reversal in the stock's trend soon.

15.10.2024 - PFE Stock was down 6.3%

• Today, Pfizer's stock showed a decline.
• The appointment of a vaccine skeptic, Robert F. Kennedy Jr., by President-elect Donald Trump to lead the HHS has created doubt and uncertainty in the market.
• While Pfizer has seen success in oncology treatments, the focus on vaccine-related news and the prevailing sentiment in the healthcare industry have had a negative impact on the stock.
• Despite indications of bullish options trading towards Pfizer from well-resourced investors, suggesting a possible future upturn, the current market trend remains bearish due to external factors.

29.09.2024 - PFE Stock was down 1.9%

• Despite reporting strong Q3 earnings and revenue beats, the market movement may have been influenced by profit-taking behavior from investors after a period of heightened demand for its COVID products.
• The heightened demand for Paxlovid and expectations of $10 billion in 2024 revenue from COVID products may have already been priced into the stock, leading to a sell-off post-earnings.
• The ongoing proxy battle with activist investor Starboard Value could have added uncertainty and pressure on the stock, contributing to the bearish movement.
• Investors might be closely monitoring Pfizer's non-COVID drug performance and the impact of new and acquired products on the company's future revenue growth, which could influence future market sentiment.

09.08.2024 - PFE Stock was up 2.3%

• The surge in Pfizer's stock was attributed to positive developments in the pharmaceutical industry, particularly related to competitors and collaborations, which increased investor confidence.
• Moderna's recent positive CHMP opinion and approval for an updated COVID-19 vaccine likely contributed to sector-wide optimism and benefitted Pfizer.
• Vaxcyte's vaccine study results, showing strong immune responses and reaching a record high, created a positive sentiment for vaccine-related companies like Pfizer.
• Pfizer's strategic clinical partnership with Acepodia to expedite development in autoimmune diseases indicated potential growth opportunities, driving up the stock price further.

04.01.2025 - PFE Stock was down 2.5%

• Pfizer surpassed earnings and revenue projections in Q4, demonstrating robust performance in its Seagen and COVID-19 product lines. However, despite this, the stock witnessed a downward trend.
• Concerns regarding Pfizer's sustainability of growth momentum, particularly in meeting financial expectations, could have prompted the market's negative response.
• Investors may have anticipated even stronger results from Pfizer, resulting in profit-taking and a temporary decline in stock value.
• The market movement may also be influenced by broader industry trends or sector-specific factors impacting pharmaceutical companies.

09.09.2024 - PFE Stock was up 2.9%

• Pfizer's stock experienced a strong bullish movement today.
• The stock rose after receiving a $1 billion investment from activist investor Starboard Value, leading to optimism about a potential turnaround for the company.
• Additionally, Pfizer won a court battle in London, which may have boosted investor confidence in the company's future prospects.
• The news of the investment and legal victory likely contributed to the bullish market movement for Pfizer today.

08.00.2025 - PFE Stock was down 2.4%

• Pfizer (PFE) experienced a strong bearish movement today.
• The market might have reacted negatively to specific news related to Pfizer, such as disappointing clinical trial results or regulatory setbacks.
• Investors could be concerned about potential challenges in Pfizer's pipeline or competitive pressures impacting its revenue outlook.
• It's essential for traders to stay updated on Pfizer's latest developments and industry trends to make informed investment decisions in the pharmaceutical sector.

26.05.2024 - PFE Stock was down 3.6%

• The bearish movement in Pfizer's stock could be attributed to concerns raised by a recent meeting discussing vaccine recommendations, potentially impacting the company's vaccine sales and future prospects.
• The news of another company's RSV shot being more effective after 18 months, compared to Pfizer's lower effectiveness midway through a second RSV season, might have negatively influenced investor sentiment towards Pfizer's vaccine portfolio.
• Negative outcomes in the healthcare sector, like Pfizer, can sometimes lead to increased scrutiny and skepticism, impacting investor confidence and stock performance.
• The overall market trend of buying blue-chip stocks on the dip might have also contributed to Pfizer's stock decline, as investors may have shifted their focus towards other opportunities in the market, leading to a relative underperformance of Pfizer's stock.

06.02.2024 - PFE Stock was up 5.2%

• Pfizer's stock saw a significant bullish surge following endorsements from prominent investors, highlighting its potential for growth and dividends.
• The positive sentiment was further fueled by Pfizer's resilience in the market, trading at a price similar to over a decade ago, making it an attractive opportunity for investors.
• Despite concerns raised by the WHO regarding resistance associated with one of Pfizer's HIV drugs, the overall market optimism and investor confidence in Pfizer's long-term prospects overshadowed these challenges.
• Analysts continue to view Pfizer as a strong buy, emphasizing its undervalued status and potential for substantial upside in the future, contributing to the bullish movement in the stock.

11.06.2024 - PFE Stock was up 1.3%

• Pfizer's bullish movement today can be attributed to the positive news regarding the advancement of its once-daily weight-loss pill, danuglipron, which shows promise in the ongoing Phase 1 study. This development indicates potential future revenue streams and market expansion for the company.
• The company's decision to move forward with the once-daily version of the weight-loss pill, despite previous setbacks, demonstrates Pfizer's commitment to innovation and addressing market needs.
• The search for a new Chief Scientific Officer following Dr. Mikael Dolsten's departure may have initially caused some uncertainty in the market, but the overall positive news regarding product development likely overshadowed this aspect, contributing to the bullish movement in the stock.

30.06.2024 - PFE Stock was down 2.0%

• Despite Pfizer delivering robust earnings with revenue exceeding expectations and achieving its first revenue growth since the COVID peak in 2022, the stock encountered a bearish trend.
• The market's response may have been influenced by the substantial decrease in reported net income, showing a 98% year-over-year decline.
• Investors could be expressing worries about Pfizer's dependency on COVID-related products, as the company faces a sharp revenue decline in that particular segment.
• Despite the overall positive market sentiment and Pfizer's increased annual profit forecast driven by strong sales of cancer and heart drugs, the negative impact of the severe net income decline on the stock price was not overcome.

30.06.2024 - PFE Stock was up 1.4%

• Pfizer's recent market movement is linked to its first sales growth since the onset of the pandemic, especially in the field of cancer treatment, demonstrating its capacity to adapt and innovate in evolving market conditions.
• Strong Q2 results, surpassing earnings per share and revenue projections, likely bolstered investor trust in the company's performance and future potential.
• Amid declines in tech stocks and surges in financials and energy stocks, Pfizer's steadfastness and emphasis on areas like cancer treatment resonated with investors, sparking increased interest and a bullish trend for the stock.